Mumbai, 30 September 2026: Colgate has successfully executed a new record Oral Health screening initiative, reaching 308,106 students across 547 CBSE-affiliated schools in Tamil Nadu and Puducherry within a 10-day sprint (17 – 28 August 2026), illustrating the scalability of multi-stakeholder partnerships in driving public health outcomes.

Serving as the principal sponsor for this initiative, Colgate aligned with the Narcotics Control Bureau (NCB), the Central Board of Secondary Education (CBSE), the Indian Dental Association (IDA) of Tamil Nadu, 2,100 dentists and 29 regional dental colleges. This coalition mobilized across 40 districts to deliver the ‘Largest Multi-Location Oral Screening’ activity, a benchmark officially recognized by the World Records Union (WRU). By structurally integrating dental professionals, educators, and civic volunteers, the campaign effectively bridged preventive oral healthcare with critical interventions regarding nutrition and substance abuse prevention.

This rapid-scale mobilization accelerates the long-term objectives of Colgate’s flagship Bright Smiles, Bright Futures® (BSBF) program. Since 1991, BSBF has established a foundation of preventive care for over 200 million children and their families across India, scaling its reach to engage over 11 million children across 35,000 schools in 2025 alone. By pairing diagnostic screenings with comprehensive oral health education, Colgate is advancing its community outreach from basic awareness to measurable, behavioral intervention.

“For nearly nine decades, Colgate has operated not just as an oral care brand, but as a systemic partner in India’s foundational health journey,” stated Shilpashree Muniswamappa, Director – ESG & Communications, Colgate (India) Limited. “This World Smile Day milestone validates our collaborative model. I’d like to thank NCB, IDA Tamil Nadu and CBSE for partnering on this vision. Screening over three lakh students in 10 days proves that public-private synergies can rapidly scale critical health interventions. While the World Record highlights the operational scale of this effort, our strategic focus remains on institutionalizing preventive habits that deliver lifelong developmental dividends for the next generation.”

This targeted mobilization operates within Colgate India’s overarching 2030 SMILE Strategy. Additionally, by systematically addressing intersectional barriers across education, financial inclusion, and water security—which has positively impacted over 640,000 beneficiaries to date through the Keep India Smiling and Rural Development programs—Colgate continues to architect holistic solutions that drive measurable social impact and community resilience in India.

Mumbai, September 30, 2026: In India, prostate cancer is the second most commonly diagnosed cancer in men, but it is not a single molecularly uniform disease. As a result, one of the biggest challenges researchers for researchers is to understand why some tumours remain relatively indolent while others become aggressive, spread beyond the prostate, and eventually develop resistance to treatment.

DSS Takara Bio India, a joint venture company between India’s DSS Imagetech Pvt Ltd and Japan’s Takara Bio Inc, supports researchers with technologies for molecular profiling, transcriptomics and low-input sequencing workflows, helping investigators generate genomic and transcriptomic insights from challenging biological samples.

“Prostate cancer is a highly heterogeneous disease, with different tumour regions within the same patient potentially carrying distinct molecular alterations. Understanding how these populations evolve and contribute to metastatic disease is therefore an important area of research. A number of recent studies on the disease have incorporated DSS Takara’s complementary technologies to illustrate the molecular events associated with metastatic progression. Together, these approaches are helping the fraternity to build a more comprehensive picture of prostate cancer—one that extends beyond what can be observed from a single tissue biopsy,” said Harkaran Dhingra, CEO, DSS Takara Bio India.

Some of DSS Takara’s technologies that have been recently incorporated in prostate cancer studies are SMART-Seq Stranded, SMART-Seq mRNA, NucleoMag NGS cleanup and ThruPLEX Tag-Seq, across tissue transcriptomics and liquid-biopsy research workflows.

Recent research demonstrates how different genomic approaches can provide complementary perspectives on prostate cancer biology:

• Tumour tissue genomics and transcriptomics can reveal molecular pathways and alterations associated with tumour evolution and metastatic progression.
• CTC transcriptomics can provide insights into tumour lineage states and molecular heterogeneity from blood-derived cells.
• cfDNA sequencing can investigate tumour-derived genomic alterations from plasma and potentially capture aspects of tumour heterogeneity over time.
• Sensitive library preparation and sequencing workflows are critical when working with challenging samples containing limited amounts of biological material.
• Liquid biopsy approaches offer researchers another way to study tumour-derived material circulating in the bloodstream.

“These approaches are particularly relevant because prostate cancer is not a single molecularly uniform disease. The ability to examine DNA and RNA across different sample types therefore offers researchers an increasingly integrated view of disease biology. As prostate cancer research moves toward increasingly comprehensive molecular profiling, the quality and sensitivity of sample-to-data workflows become increasingly important,” adds Mr. Harkiran. As the field continues to evolve, integrating information from tumor tissue, CTCs and circulating DNA could help researchers better understand how prostate cancer develops, progresses and changes over time.

New Delhi, September 25, 2026: Cloudnine Group of Hospitals, India’s premium birthing centre, conducted a first-of-its-kind series of 17 hands-on simulation and clinical training workshops in New Delhi, designed to strengthen the practical skills of doctors and healthcare professionals across the perinatal care spectrum.

The programme brought together experts in obstetrics and gynaecology, neonatology, paediatrics, fetal medicine, obstetric anaesthesia, prenatal genetics, paediatric intensive care and nursing. Over 150 clinicians, including junior doctors, obstetricians, nurses and trainees from leading medical colleges and hospitals across Delhi NCR, participated in these workshops. Sessions were led by senior Cloudnine clinicians and renowned faculty, bringing together diverse clinical expertise and global best practices.

The 17 specialised workshops covered critical areas across maternal, fetal and newborn care, including complex caesarean deliveries, prenatal genetics, fetal medicine, advanced life support in obstetrics, neonatal simulation, obstetric anaesthesia, hypoxic-ischaemic encephalopathy (HIE), recurrent pregnancy loss, paediatric intensive care, neonatal POCUS, lactation after loss, perinatal law and liability, and critical newborn care.

Dr. R. Kishore Kumar, Founder-Chairman and Executive Director, Cloudnine Group of Hospitals, said, “Perinatal care involves critical decisions for both mothers and newborns. These workshops give doctors an opportunity to learn from experienced experts to make childbirth very safe. Cloudnine has been conducting these workshops across cities over the years with a strong focus on making childbirth safer. Like simulation training has helped make air travel safer, hands-on training helps doctors prepare for real-life situations. The focus is on practical learning, teamwork and sharing knowledge across specialties. Our aim is to help doctors feel better prepared to care for mothers and babies.The sessions also encourage learning and collaboration across specialties. Our aim is to help doctors feel better prepared to care for mothers and babies.”

Adding further he says “The programme placed a strong emphasis on experiential learning, with dedicated simulation and procedural workshops allowing participants to practise clinical techniques and respond to real-world scenarios in a structured learning environment”

Hyderabad: 24^th September, 2026: Healthark, a healthcare and life sciences strategy and capability-building firm specializing in building niche and specialized GCCs, brought together senior leaders from global pharmaceutical, medtech, healthcare and technology companies at RISE Health Innovation Summit 2026 in Hyderabad, with a strong focus on how India can become a global hub for high-value healthcare and life sciences capabilities.

A key highlight of the RISE summit was the launch of Healthark’s new publication, Unlocking India as the Strategic Hub for Life Sciences & Healthcare GCCs, by Shri D. Sridhar Babu, Hon’ble Minister for Information Technology, Electronics & Communications, Industries & Commerce, and Legislative Affairs, Government of Telangana.

The publication examines the evolution of India’s life sciences and healthcare GCC landscape and the opportunity for global companies to build increasingly sophisticated capabilities in India across regulatory affairs, clinical development, medical affairs, quality, analytics, digital, AI and other specialised functions.

It also brings together perspectives and experiences from industry leaders associated with Novo Nordisk, Roche, Opella and other global organisations, alongside Healthark’s own experience working with healthcare and life sciences companies. Key statements by these leaders are annexed.

India’s GCC opportunity is moving beyond scale

The central theme emerging from RISE 2026 was that the next phase of India’s GCC journey will be defined not simply by the number of people employed or functions relocated to India, but by the value, complexity and global ownership of the work performed here.

Global healthcare and life sciences companies are increasingly looking at India for specialised scientific and business capabilities, access to deep talent pools and the ability to combine domain expertise with technology, analytics and AI.

The summit comprised a two-day virtual program on September 22 – 23, followed by a live summit in Hyderabad on September 24. Across the three days, RISE 2026 brought together speakers from Novo Nordisk, Carelon Global Solutions, Opella, Thermo Fisher Scientific, Roche, Deloitte, Bosch, Medtronic, Sandoz, 4baseCare, Biostate, CRISPR Bits and MedGenome, among others who shared insights on how India’s role in global healthcare and life sciences is changing from the growth of specialized capabilities and R&D to the increasing use of AI, analytics, engineering, genomics and biotechnology to solve complex global problems.

Addressing the audience, Minister D. Sridhar Babu said “RISE 2026 brings together an important cross-section of leaders from healthcare, life sciences, technology, GCCs, research and innovation at a time when India’s role in the global economy is evolving significantly. Hyderabad is particularly well positioned for this next phase, with a strong life sciences ecosystem, deep technology and engineering talent, and an increasingly connected innovation landscape. Our opportunity in Telangana is to bring these strengths together and create an ecosystem where science, technology, talent and industry work together to solve real problems”

Commenting on the event, Dr. Purav Gandhi, Founder & CEO, HealthArk, said: “The conversation around GCCs is changing. For healthcare and life sciences companies, the opportunity is no longer simply about moving more work to India. It is about deciding which capabilities can be built here, creating the right operating model and developing teams that can take global ownership. We believe India can become one of the most important global centres for specialised healthcare and life sciences capabilities.”

Sudeep Krishna, Co-Founder & President, HealthArk, added: “Building a successful GCC requires much more than access to talent. Companies need the right domain capabilities, leadership, operating model and integration with their global organisation. Healthark’s focus is to help companies navigate that journey – from strategy and capability design through to building and scaling teams on the ground.”

Commenting on the event, co-authors of the book added, “India’s role within global organisations is evolving well beyond traditional delivery. We are seeing India-based teams increasingly take ownership of complex global capabilities, bring together technology, talent and business expertise, and contribute directly to enterprise-wide priorities.” – John Dawber, Managing Director, India GCC at Novo Nordisk

“India’s GCC journey has moved well beyond scale. What is increasingly important is the ability to build distinctive capabilities, take ownership of complex global priorities and create value that can travel across the organisation.” – Nilay Shastri, General Manager at Roche Services and Solutions, India

“India’s Life Sciences and Consumer Healthcare ecosystem is entering an exciting new phase, supported by a growing economy, young workforce and strong education ecosystem producing talent across engineering, medicine, and technology. The combination of talent, new ways of working, and strong global partnerships can help India’s GCCs move from operational scale to greater global impact.” – Chandani Palshetkar, Global Head of GCC Strategy & Services at Opella

The live summit opened with the keynote address, “Shaping the Future of Indian Healthcare,” by Dr. G. V. Rao, Director, AIG Hospitals, focusing on the opportunities and transformations shaping the future of healthcare in India. He added“India’s healthcare ecosystem is entering a defining phase, shaped by advances in technology, changing patient expectations and the growing need for more accessible and integrated care,”.

Across three days, RISE 2026 brought together perspectives from government, healthcare, life sciences, technology, research and academia around a common question: how do we translate the extraordinary pace of scientific and technological change into meaningful, scalable impact.

Five health check-up and cancer screening camps were organised simultaneously across different locations today, marking the formal roll-out of the initiative. To ensure comprehensive care beyond screening, the Sankalp Cancer Care Foundation has also partnered with the Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), Rohini, to take care of any further medical needs, diagnosis, and treatment required after the screenings.

The initiative was announced by the company, underscoring its continued commitment to the health and wellbeing of the labour communities working across its project sites. Ahead of the camps, the implementing partner conducted awareness sessions across project locations, sensitising beneficiaries to the importance of preventive screening and encouraging their participation.

Speaking on the initiative, Mr. Pradeep Aggarwal, Founder and Chairman, Signature Global (India) Ltd. said, “At Signature Global, we believe that true progress is incomplete without ensuring the health and wellbeing of the communities that build it with us. Our labour force works tirelessly on our project sites, and it is our responsibility to ensure that their health is never overlooked. Early detection saves lives, and through this mega cancer pre-screening initiative, we are taking a meaningful step towards making preventive healthcare accessible to those who need it most.

Through our Aarogya Rise programme, in partnership with the Sankalp Cancer Care Foundation and their collaboration with the Rajiv Gandhi Cancer Institute & Research Centre, we are ensuring that this is not just a one-time screening exercise but a complete continuum of care, from screening to treatment.”

The initiative follows a structured, end-to-end approach. The Sankalp Cancer Care Foundation manages the entire process, from on-ground awareness sessions and beneficiary sensitisation to clinical screening and, where required, referral for further treatment through RGCIRC. This is designed to ensure informed participation and maximise the long-term impact of the camps. The camps are organised by Signature Global Foundation and Sankalp Cancer Care Foundation in collaboration with RGCIRC, Rohini, as a Signature Global Foundation CSR initiative.

All services at the camps are free. Beneficiaries can avail of blood pressure, diabetes and ECG checkups, cancer awareness talks, and a comprehensive general health checkup for both men and women. Cancer screening includes clinical screening for oral cancer, clinical breast cancer screening and Pap smear-based cervical cancer screening for women, and prostate cancer consultation and screening for men. Specific lab tests, including HB, PSA and Pap Smear, will also be conducted. In addition, the camps offer eye checkups with free spectacle distribution, and free medicines and sanitary pads.

Guided by the vision of Founder & Chairman Mr. Pradeep Aggarwal, Signature Global Foundation has long championed inclusive community development through purposeful initiatives spanning education, healthcare, women’s empowerment, elderly care, and environmental sustainability, positively impacting thousands of lives across Gurugram and the NCR region.

To date, the Foundation has reached over 95,720 students through its education programme Paathshaala, empowered 20,157 girls through its flagship Jagruk Beti Swasth Beti programme, and provided healthcare access to over 33,722 beneficiaries through its Aarogya Rise mobile healthcare initiative. It has also enabled digital literacy for 1,695 beneficiaries through Tech Udaan and supported environmental sustainability through Ek Ped Maa Ke Naam, under which 11,072 trees have been planted. In addition, the Foundation extends operational support for elderly care through Tara Sansthan and Mumukshu Bhawan, reaching 1,052 beneficiaries. It also partners with the Dev Animal Voluntary Organisation and Apna Ghar Sansthan for old-age care, Shri Chetan Das Goverdhan Sansthan for animal welfare, and the Ram Nath Kovind Foundation for vocational training.

Looking ahead, Signature Global Foundation plans to expand its CSR footprint with upcoming programmes including STEM Labs, a Scholarship Programme, and a Skill Centre in Vrindavan, reaffirming its commitment to building a healthier, more inclusive, and compassionate society.

Bengaluru, September 21, 2026: In Bengaluru, honking has become as much a part of the daily commute as traffic itself. At signals, in bumper-to-bumper roads, and even when there is nowhere for vehicles to move, the instinct to honk often comes automatically. This World Heart Day, SPARSH Hospitals is turning this everyday Bengaluru behaviour into a city-wide awareness conversation with the launch of ‘Horn Don’t Maadi’.

Built around a simple observation that honking does not make traffic move, the campaign encourages commuters to rethink unnecessary and habitual honking and consider the impact of repeated traffic noise and everyday commute-related stress on their overall wellbeing. Importantly, ‘Horn Don’t Maadi’ is not a campaign against using the horn when it is required for safety. Instead, it seeks to distinguish between necessary honking and the habitual use of the horn driven by impatience, frustration or the belief that making more noise can somehow make traffic move faster.

The campaign’s central thought asks Bengaluru a simple question: “Can honking move the traffic? If not, what is all this noise doing to us?” By connecting a highly relatable urban behaviour with heart health, SPARSH Hospitals aims to take the World Heart Day conversation beyond conventional health messaging and into the everyday environment experienced by millions of Bengaluru commuters.

“We wanted to create a World Heart Day campaign that people in Bengaluru would immediately recognise as their own. Honking has become such a familiar part of our daily commute that we rarely stop to question whether every honk is actually necessary. With ‘Horn Don’t Maadi’, our intention is simply to encourage a moment of pause. If the traffic is not moving, another honk is unlikely to change it. But choosing not to honk unnecessarily can make the environment around us a little calmer. As a healthcare organisation, we believe prevention and wellbeing are also shaped by the everyday environments and behaviours around us” said Dr. Sharan Shivaraj Patil, Founder, Chairman and Chief Orthopaedic Surgeon, SPARSH Group of Hospitals.

“An occasional honk is not the concern. It is repeated exposure to unnecessary and stressful noise that can add to the body’s stress response. When these stressors are experienced repeatedly, they can contribute to chronic stress, which is one of several factors that influence cardiovascular health,” said Dr. (Prof) Ranjan Shetty, Lead Consultant, Cardiologist and Group Medical Director, SPARSH Hospitals.

The campaign is rooted in the understanding that loud or unexpected noise can activate the body’s fight-or-flight response, with stress hormones such as adrenaline and cortisol involved in the body’s response to stress. While an occasional honk is not the concern, repeated exposure to stressful noise and traffic environments can contribute to physiological stress over time.

SPARSH Hospitals is therefore using honking as an entry point into a broader conversation around stress, wellbeing and cardiovascular health, without suggesting that individual honks directly cause heart disease or that traffic noise is the sole cause of cardiovascular risk.

The campaign recognises that heart health is influenced by several established factors, including hypertension, diabetes, smoking, obesity, lifestyle and chronic stress. Persistent noise can also affect sleep and overall wellbeing, making the everyday environment an important part of the larger health conversation.

Rather than keeping the initiative limited to hospital communication or conventional awareness messaging, SPARSH Hospitals will take ‘Horn Don’t Maadi’ directly into Bengaluru’s roads, communities and daily conversations. The campaign will use a mix of public sign-ups, hospital and community engagement, radio and social media interventions, street vox pops, interactive traffic polls and doctor-led conversations to bring commuters into the conversation. Through street-level interactions, the campaign will explore how Bengaluru experiences its honking culture and encourage people to reflect on when they actually need to use their horns.

The campaign will also feature influencer-led content under ‘Honk Not Okay Please’, extending the conversation into social media through relatable, city-specific content designed to encourage participation and discussion.

The objective of ‘Horn Don’t Maadi’ is not to eliminate honking from Bengaluru’s roads. The horn remains an important safety tool and should be used whenever the situation requires it. Instead, SPARSH Hospitals is seeking to make unnecessary and habitual honking less normalised.

The campaign encourages commuters to pause before reaching for the horn, particularly when traffic is stationary, when there is no immediate safety concern or when the honk is simply a response to frustration. Through this approach, SPARSH aims to create greater awareness around the relationship between everyday traffic stress, repeated noise and wellbeing, while encouraging a more considerate commuting environment.

At a time when Bengaluru’s traffic is an unavoidable part of everyday life, ‘Horn Don’t Maadi’ puts the focus on one element commuters can consciously reconsider: the unnecessary honk. The campaign’s message is simple: Use the horn when safety requires it, not as a default response to traffic.

Suganthy’s journey at Apollo Hospitals is one of growth shaped by instinct, commitment and an exceptional ability to build relationships. Beginning as a junior PR executive, she grew alongside Apollo, taking on larger responsibilities as the organisation expanded across the country. Over four decades, she has emerged a deeply respected voice among stakeholders, building a reputation founded on credibility, transparency and integrity. Her journey is a powerful reminder that careers are not defined by where they begin, but by the trust earned and the difference made along the way.

She has also held leadership positions within the Public Relations Society of India and the wider PR fraternity, including serving as the first woman Chairperson of PRSI in its four-decade history. Her contribution to the profession has been recognised through several honours, including the PRSI National Award for Outstanding Contributions to Healthcare Communications, presented at the International Public Relations Festival in New Delhi, and induction into the PR Hall of Fame at the Chanakya Awards in Goa. She has also given generously of her time as a mentor, lecturing and sharing knowledge with corporate, academic and professional institutions.

Commenting on the recognition, Ms Suganthy said, “This recognition is deeply meaningful to me, as my journey has grown alongside Apollo Hospitals for over four decades. I have had the privilege of witnessing Apollo grow into a globally respected healthcare institution, while finding opportunities to learn, contribute and grow at every stage. I remain deeply grateful to my colleagues, the media and the many people who have been part of this journey. I hope my experience inspires young PR professionals to build their careers on resilience, integrity and a commitment to excellence.”

The award celebrates Suganthy Sundararaj’s enduring contribution to healthcare communications and her commitment to fostering transparency, trust and understanding between hospitals and the public they serve.

The ASG Fellowship Programme is a post-postgraduate subspecialty training programme in ophthalmology, designed for ophthalmologists seeking advanced expertise beyond their postgraduate qualifications. The programme offers focused training in Retina, Phaco-Refractive Surgery, Phaco-Medical Retina, Phaco-Oculoplasty, and Phaco-Squint.

The six graduating fellows underwent intensive training combining hands-on clinical experience, surgical exposure, mentorship, and academic learning. The programme focuses on developing advanced clinical and surgical skills, sound clinical decision-making, and the ability to manage complex cases in specialised areas of ophthalmology.

The convocation brought together senior ophthalmologists, faculty members, fellows and distinguished guests to celebrate the achievements of the graduating batch and mark their transition from fellowship training to independent professional practice.

The academic programme included interactions between mentors and fellows, with discussions focusing on the fellowship journey, academics, and ethics in ophthalmic practice. The event also recognised the achievements of the graduating fellows through the presentation of fellowship certificates and awards.

The academic programme is supported by ASG Hospital’s Academic Cell, led by Dr. Ganesh Pillay, Chief of Research & Academics and Regional COO (Central India), ASG Hospital Limited; Dr. Mayank Sharma, Director – Induction & Training and Regional COO (Rajasthan), ASG Hospital Limited; and Dr. Koushik Tripathy, Secretary, Academic Cell and Medical Director, ASG Eye Hospital, Kolkata. The Academic Cell plays a key role in strengthening structured learning, academic development, and continuous professional training across ASG’s ophthalmic ecosystem.

Dr. Arun Singhvi, MD & CEO, ASG Hospital, emphasised the importance of developing specialised talent in ophthalmology and addressing the growing need for skilled subspecialists. He highlighted the role of structured advanced training and continuous upskilling in bridging the talent gap while ensuring that specialised eye care remains responsive to the needs of the population.

The six graduating fellows joined the growing community of 28 ophthalmologists who have completed training through the ASG Fellowship Programme, taking their specialised skills forward to contribute to advanced eye care in their respective professional settings.

The Fellowship Programme reflects ASG Hospital’s commitment to extending its contribution to ophthalmology beyond patient care by nurturing skilled subspecialists, promoting surgical excellence and strengthening the ecosystem for advanced ophthalmic training.

As the future unfolds, ASG Hospital Limited plans to develop its academic program further through provision of research programs, international observerships as well as using the latest diagnostic and surgical facilities available today.

Through continuous upgrading of ophthalmologists, ASG will ensure that there is a sustained supply of talent to improve the standards of specialized eye care services.

Initiative involved 2,174 doctors across India and focused on early screening and awareness around regular blood pressure monitoring 

Mumbai, August 26^th, 2026: A large-scale blood pressure (BP) screening initiative conducted by Alembic Pharmaceuticals Limited, involving 40,468 patients and 2,174 doctors across India between May 7 and May 20, has earned the company recognition in the Asia Book of Records for achieving the record of “Maximum Patients Screened for Blood Pressure in a Fortnight.”

Undertaken to encourage early screening, improve awareness of hypertension-related risks and promote regular blood pressure monitoring, the screening drive formed part of Alembic Pharmaceuticals Limited’s broader focus on cardiovascular, renal and metabolic health. These themes were further explored at the company’s Triad Symposia, Mumbai, a platform that brought together cardiologists, nephrologists, endocrinologists and physicians to discuss the evolving approach to cardiovascular, renal and metabolic health. The symposia highlighted the interconnected nature of hypertension, diabetes and early kidney disease, and the importance of early screening, risk assessment and preventive care to address disease progression and reduce the risk of cardiovascular and chronic kidney disease.

Experts highlighted the need to look at the individual as a whole rather than treating each condition in isolation. They also spoke about seeing hypertension among younger Indians, including people in their 20s and 30s, with factors such as physical inactivity, smoking, alcohol consumption, dietary habits and stress adding to the risk. The concern is compounded by the fact that hypertension can remain undiagnosed, untreated, or uncontrolled in a majority of individuals, leading to heart- and kidney-related complications if not addressed through timely intervention.

The success of the screening drive and the broader discussions around proactive healthcare were supported by the active contribution of the company’s senior leadership team, including Mr. Kunal Mukhopadhaya, Senior Vice President – CV Business; Mr. Ashish Singh Chauhan, Vice President; Dr. Sanjay Jain, Vice President Medical Team ; Mrs. Ashvini Mundhada, Deputy General Manager; Mr. Vinod Bhat, AGM, along with the entire Alembic Specia Speciality Sales & Marketing Team.

The event concluded in the presence of leading doctors, including Hon’ble Dr. Ashok Kirpalani, Dr. B. C. Kalmath, Dr. Sandip Fulpagare, Dr. Chetan Shah, Dr. Gaurav Daga, Dr. Johann Verghese, Dr. Rohit Barnabas, Dr. Manjiri Karlekar, Dr. Vikas Bharati and Dr. Nitin Sonavane, along with 65 other doctors from across Mumbai. The initiative and Alembic Pharmaceuticals Limited’s patient-first approach received widespread appreciation from the medical fraternity.

The Asia Book of Records recognition marks a significant milestone for Alembic that reflects the larger purpose behind the screening initiative. The initiative aims to make important health checks more accessible, encourage people to monitor their health and help identify risks before they become more difficult to manage.